The FGFR3 mutation is related to favorable pT1 bladder cancer

Journal of Urology

Volumn 187, Issue 1, 2012, Pages 310-314

  Van Rhijn, Bas W G ^a,c,d,e   Van Der Kwast, Theo H ^b,d   Liu, Liyang ^c   Fleshner, Neil E ^a   Bostrom, Peter J ^a   Vis, André N ^d   Alkhateeb, Sultan S ^a   Bangma, Chris H ^d   Jewett, Michael A S ^a   Zwarthoff, Ellen C ^d   Zlotta, Alexandre R ^a,c   Bapat, Bharati ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

carcinoma; disease progression; fibroblast growth factor; genes; p53; receptor; type 3; urinary bladder

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

AGED; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM STAGING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 83555162466     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.09.008     Document Type: Article

References (23)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. B.W. van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430
3. D.H. Sobin, and C. Wittekind TNM Classification of Malignant Tumours 6th ed. 2002 Wiley-Liss New York 199 202
4. A.M. Nieder, M. Brausi, and D. Lamm Management of stage T1 tumors of the bladder: International Consensus Panel Urology 66 suppl. 2005 108
5. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
6. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
7. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303
8. B.J. Schmitz-Drager, P.J. Goebell, and T. Ebert P53 immunohistochemistry as a prognostic marker in bladder cancer Playground for urology scientists? Eur Urol 38 2000 691
9. B.W. van Rhijn, A.N. Vis, and T.H. van der Kwast Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome J Clin Oncol 21 2003 1912
10. C. Billerey, D.K. Chopin, and M.H. Aubriot-Lorton Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955
11. A.A. Bakkar, H. Wallerand, and F. Radvanyi FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108
12. B.W.G. van Rhijn, T.H. van der Kwast, and A.N. Vis FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma Cancer Res 64 2004 1911
13. H.B. Grossman, M. Liebert, and M. Antelo P53 and RB expression predict progression in T1 bladder cancer Clin Cancer Res 4 1998 829
14. S. Hernandez, E. Lopez-Knowles, and J. Lloreta FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis Clin Cancer Res 11 2005 5444
15. G. Dalbagni, D.J. Parekh, and L. Ben-Porat Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder BJU Int 99 2007 281
16. S.F. Shariat, C. Bolenz, and G. Godoy Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy J Urol 182 2009 78
17. J.M. van Oers, I. Lurkin, and A.J. van Exsel A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine Clin Cancer Res 11 2005 7743
18. W. Otto, S. Denzinger, and S. Bertz No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer Int J Cancer 125 2009 2205
19. N.A. Mungan, K.K. Aben, and M.P. Schoenberg Gender differences in stage-adjusted bladder cancer survival Urology 55 2000 876
20. M. Horstmann, R. Witthuhn, and M. Falk Gender-specific differences in bladder cancer: a retrospective analysis Gend Med 5 2008 385
21. F. Saint, J.J. Patard, and P. Maille Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer J Urol 167 2002 364
22. H.W. Herr, S.M. Donat, and G. Dalbagni Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177 2007 75
23. R.T. Divrik, A.F. Sahin, and U. Yildirim Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial Eur Urol 58 2010 185